COVID-19: Pharmacovigilance's Biggest Test.
We are undergoing the biggest vaccination program in history, aiming to finally bring the COVID-19 pandemic to an end. This presents pharmacovigilance’s with its biggest test yet.
In my line of work you come across new companies everyday, however, few are as forward-thinking and unique as Norman Health. I spoke to the company's founder and Managing Director, Jan-Wilem Eleveld.
For decades, we’ve been talking about how NGS will change the world. But what if NGS was only the start?
Only 30% of executive positions and 18% of board seats are held by women in biotech. I spoke to industry expert, Melissa Gammell, to find out where we're going wrong, how we get more women into biotech and how we keep them there.
In this episode of CM Conversations, our lab equipment specialist Lucy Smith spoke with Melissa Gammell, Vice President of Business Development at Matphil Technologies about the challenges facing women in biotech.
In this episode, our specialist in the lab equipment space, Lucy Smith, spoke with CEO of Elementar Americas Ryan Titmas. Lucy spoke to Ryan about what it takes to get to the top, as well as some of the lessons he’s learned in his career so far.
Coronavirus has provided us with a very large and extremely recent data set for research, patient populations and how different ethnic minorities are being affected versus the research. And the early indicators are that those from minority background
Billions of dollars have been pumped into medicinal cannabis. It’s popular with patients. The public’s perceptions are changing (for the better) and the competition isn’t nearly as tough as other markets in pharmaceuticals.
Decentralised, virtual, home, remote… whatever the name of this type of trial, it's widely agreed they will be crucial to advancing healthcare.
Analytical instruments are crucial to manufacturing and R&D, helping analyse materials to establish their composition. This data makes it easier to simplify processes, increase efficiency and productivity.
Returning from CPhI 2019, in Frankfurt, the words of Eric Langer, President of Bioplan Associates, have stuck with me. Forget the innovation, are biosimilars the real 'workhorse' carrying biopharma to bigger and better things?
Pharma packaging is in transition. Companies are now pushing boundaries, furthering their offerings and innovating to be seen as true healthcare partners.
It’s no secret that pharmaceutical manufacturing has been on the rise in the East, with both China and India emerging as major manufacturing hubs.
In 1971 then-US President Richard Nixon famously declared war on drugs, naming drug abuse ‘public enemy number one’. That war’s now been raging for more than 45 years at an estimated cost of over $1 trillion USD.
When I first made the decision to write an article about CRO size and what impact it has on service, the idea revolved around a ‘David vs Goliath’ narrative. I was going to write about major CROs compared to smaller CROs, then (spoiler alert) come...